---
figid: PMC6753603__f1000research-7-14236-g0001
figtitle: Schematic overview of the two most common pathways with genetic alterations
  in thyroid cancerâ€”mitogen-activated protein kinase (MAPK) and phosphatidylinositide
  3-kinase (PI3K) pathways
organisms:
- NA
pmcid: PMC6753603
filename: f1000research-7-14236-g0001.jpg
figlink: /pmc/articles/PMC6753603/figure/f2/
number: F2
caption: The pathways can be activated by receptor tyrosine kinases (RTKs) being activated
  by growth factors or by overexpression of the receptor. Constitutive activation
  of the signaling pathways can be caused by mutations along the pathway, such as
  BRAF, RAS, PI3K, AKT, or mammalian target of rapamycin (mTOR), mutations in tumor
  suppressor genes, such as neurofibromin 1 (NF1) or phosphatase and tensin homolog
  (PTEN) mutations, or fusion RTKs, such as those in RET, neurotropic tropomyosin
  receptor kinase (NTRK), or anaplastic lymphoma kinase (ALK). Drugs that can inhibit
  at critical points in the pathway are listed in grey boxes. FGFR, fibroblast growth
  factor receptor; TSC1, tuberous sclerosis complex 1; TSC2, tuberous sclerosis complex
  2; VEGFR, vascular endothelial growth factor receptor.
papertitle: Recent advances and emerging therapies in anaplastic thyroid carcinoma.
reftext: Maria E. Cabanillas, et al. F1000Res. 2018;7:F1000 Faculty Rev-87.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9506511
figid_alias: PMC6753603__F2
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC6753603__F2
ndex: 92567162-deef-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6753603__f1000research-7-14236-g0001.html
  '@type': Dataset
  description: The pathways can be activated by receptor tyrosine kinases (RTKs) being
    activated by growth factors or by overexpression of the receptor. Constitutive
    activation of the signaling pathways can be caused by mutations along the pathway,
    such as BRAF, RAS, PI3K, AKT, or mammalian target of rapamycin (mTOR), mutations
    in tumor suppressor genes, such as neurofibromin 1 (NF1) or phosphatase and tensin
    homolog (PTEN) mutations, or fusion RTKs, such as those in RET, neurotropic tropomyosin
    receptor kinase (NTRK), or anaplastic lymphoma kinase (ALK). Drugs that can inhibit
    at critical points in the pathway are listed in grey boxes. FGFR, fibroblast growth
    factor receptor; TSC1, tuberous sclerosis complex 1; TSC2, tuberous sclerosis
    complex 2; VEGFR, vascular endothelial growth factor receptor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - KDR
  - FLT4
  - FLT1
  - FGFR2
  - FGFR1
  - RET
  - FGFR3
  - KRAS
  - HRAS
  - NRAS
  - NF1
  - NTRK1
  - NTRK2
  - NTRK3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - ALK
  - PTEN
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - TSC2
  - TSC1
  - CCL26
  - MTOR
  - EPHB2
  - MAPK1
  - MAPK3
  - Tyrosine
  - lenvatinib
  - vemurafenib
  - dabrafenib
  - PLX8394
  - crizotinib
  - ceritinib
  - cobimetinib
  - trametinib
  - selumetinib
  - RO5126766
  - everolimus
  - temsirolimus
  - MLN0128
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
